CompreVie develops human in vitro systems using microfluidic technology and tissue engineering to enable precise screening of substances for pharmaceutical, chemical, and cosmetic applications. Their smart skin biochip mimics mechanical tissue damage and topical product application, providing a reliable alternative to traditional animal testing methods.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional animal testing methods for pharmaceutical, chemical, and cosmetic applications are often unreliable and raise ethical concerns. Screening substances using conventional in vitro systems lacks the complexity of human tissues, leading to inaccurate predictions of product efficacy and safety.
Solution
CompreVie develops human in vitro systems using microfluidic technology and tissue engineering to provide a more accurate and ethical approach to substance screening. Their smart skin biochip mimics mechanical tissue damage and topical product application, offering a reliable alternative to animal testing. The platform enables acute to chronic in vitro substance screening, providing insights into product behavior within a human-relevant environment. This allows for precise evaluation of pharmaceutical, chemical, and cosmetic products, improving the development process and reducing reliance on animal models.
Target Audience
The primary customers are pharmaceutical, chemical, and cosmetic companies seeking reliable and ethical methods for substance screening and product development.
Features
- Microfluidic technology for precise control of the cellular environment
- Tissue engineering techniques to create human-relevant in vitro systems
- Smart skin biochip that mimics mechanical tissue damage
- Capability for topical product application simulation
- Acute to chronic in vitro substance screening